HK Stock Market Move | QUNABOX GROUP (00917) rises over 3%, receives voluntary lock-up undertakings from directors and parties acting in concert
QUNABOX GROUP (00917) rose over 3%, up 2.89% as of press time, at HK$6.24, with a turnover of HK$28.5225 million.
QUNABOX GROUP (00917) rose over 3%, up 2.89% as of press time, at HK$6.24, with a turnover of HK$28.5225 million.
On the news front, QUNABOX GROUP announced that on October 20, 2026, it received voluntary undertakings from Chairwoman and Executive Director Ms. Yin Juehui, Mr. Cao Liwen, Executive Director Mr. Huang Aihua, Group Chief Financial Officer Ms. Yin Juelian, Mr. Wu Wenhong, and Executive Director Mr. Qian Jun (collectively the "Lock-up Shareholders"). The Lock-up Shareholders further voluntarily undertook that, during the 12-month period from October 20, 2026 to October 19, 2027, they will not sell any of the 103 million shares of the company they hold directly or indirectly through trusts or corporations controlled by them.
The announcement stated that the Lock-up Shareholders made the voluntary undertakings to demonstrate their firm confidence in the group's long-term value and development prospects. The Lock-up Shareholders also confirmed that, during the period from May 27, 2024 (i.e., the date of the company's listing on the Main Board of The Stock Exchange of Hong Kong Limited) to the date of this announcement, none of the Lock-up Shareholders had sold any shares.
Related Articles

CLSA: Z.AI (02513) Has Established a High-Quality Customer Base in Markets Outside China; Target Price HK$1,907

HK Stock Market Move | KINGDEE INT'L (00268) rises over 7%; Q3 net new ARR approximately RMB 191 million; company's AI order conversion begins to accelerate.

Late-stage trial meets primary endpoint! Eli Lilly (LLY.US) plans to expand Omvoh indication for pediatric ulcerative colitis treatment
CLSA: Z.AI (02513) Has Established a High-Quality Customer Base in Markets Outside China; Target Price HK$1,907

HK Stock Market Move | KINGDEE INT'L (00268) rises over 7%; Q3 net new ARR approximately RMB 191 million; company's AI order conversion begins to accelerate.

Late-stage trial meets primary endpoint! Eli Lilly (LLY.US) plans to expand Omvoh indication for pediatric ulcerative colitis treatment






